Pulmonary nodules should be assessed by size, morphology, patient-specific risk, location, and change on serial imaging, rather than size alone.
2
Adequate tumor tissue for histology and molecular profiling can inform perioperative treatment choices and subsequent options in non-small cell lung cancer.
3
For selected patients with resectable stage 2 or 3 non-small cell lung cancer, treatment may include neoadjuvant chemotherapy plus immunotherapy followed by surgery.
4
In carefully selected patients with limited metastases, local treatment may be considered with systemic therapy, based on disease distribution, response, and feasibility.
5
Robotic surgery does not replace oncologic principles, including adequate margins, anatomical resection when indicated, and systematic lymph node assessment.
Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.